AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18473176 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 12
Study 18473176 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 12
Study 15785901 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidopexy
Number of subjects: 31
Study 15785901 — intervention group
Group type: COMPARATOR
Intervention: Diathermy excision
Number of subjects: 31
Study 11918761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate-buffered PD solution (34 mmol/L, pH 7.4)
Number of subjects: 25
Study 11918761 — intervention group
Group type: COMPARATOR
Intervention: Lactate-buffered PD solution (35 mmol/L, pH 5.5)
Number of subjects: 25
Study 11918761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both bicarbonate and lactate buffered PD solutions
Number of subjects: 25
Study 9972755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalad-oriented Tuohy needle bevel
Number of subjects: 500
Study 9972755 — intervention group
Group type: COMPARATOR
Intervention: Lateral-oriented Tuohy needle bevel
Number of subjects: 500
Study 7762389 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline nasal spray once daily at night
Number of subjects: 20
Study 7762389 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline nasal spray three times daily
Number of subjects: 20
Study 7762389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2221729 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (3 tablets daily for one month)
Number of subjects: 42
Study 2221729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 342043 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ampicillin (1 g applied to the wound)
Number of subjects: 374
Study 342043 — intervention group
Group type: COMPARATOR
Intervention: Wound irrigation with 1% cetyl trimethyl ammonium bromide (Savlon)
Number of subjects: 374
Study 6196515 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose neuraminidase-treated allogeneic blasts
Number of subjects: 0
Study 6196515 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific monoclonal antibodies or autologous cytotoxic T-cells
Number of subjects: 0
Study 31305950 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness activity (1-minute duration)
Number of subjects: 164
Study 31305950 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness activity
Number of subjects: 164
Study 29806411 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐made nickel‐titanium shape memory alloy stepped plate (group A)
Number of subjects: 6
Study 29806411 — intervention group
Group type: COMPARATOR
Intervention: Calcaneal plate (group B)
Number of subjects: 6
Study 29806411 — intervention group
Group type: COMPARATOR
Intervention: Cannulated compression screws (group C)
Number of subjects: 6
Study 26802011 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered, tablet computer-based self-monitoring system
Number of subjects: 63
Study 26802011 — intervention group
Group type: COMPARATOR
Intervention: Conventional self-monitoring method
Number of subjects: 63
Study 25503160 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc in sodium alginate suspension (P‐AG)
Number of subjects: 36
Study 25503160 — intervention group
Group type: COMPARATOR
Intervention: Azulene gargle (control)
Number of subjects: 36
Study 22150876 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (TG): grafted using hydroxyapatite
Number of subjects: 20
Study 22150876 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG): left to heal without grafting
Number of subjects: 20
Study 20854207 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine gel (0.001%, 0.005%, or 0.02%) once daily on Days 1 and 10 and twice daily on Days 2-9
Number of subjects: 18
Study 20854207 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine gel (0.001%, 0.005%, or 0.02%)
Number of subjects: 18
Study 17460126 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized alert tool for pharmacists
Number of subjects: 11100
Study 17460126 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11100
Study 16039775 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8 F stent
Number of subjects: 34
Study 16039775 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 F stent
Number of subjects: 34
Study 16039775 — intervention group
Group type: COMPARATOR
Intervention: Control group (lower urinary symptoms from other causes)
Number of subjects: 34
Study 11950252 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 5 mg
Number of subjects: 0
Study 11950252 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 10 mg
Number of subjects: 0
Study 11950252 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg BID
Number of subjects: 0
Study 11950252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11950252 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 5 mg and 10 mg
Number of subjects: 0
Study 9709329 — intervention group
Group type: EXPERIMENTAL
Intervention: Padded trial
Number of subjects: 39
Study 9709329 — intervention group
Group type: COMPARATOR
Intervention: Unpadded trial
Number of subjects: 39
Study 8133413 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthrinse
Number of subjects: 50
Study 8133413 — intervention group
Group type: COMPARATOR
Intervention: Sterile colored water control
Number of subjects: 50
Study 2803090 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg/d)
Number of subjects: 12
Study 2803090 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg/d)
Number of subjects: 12
Study 2803090 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 12
Study 2803090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1023955 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam in glycoferol-alcohol-benzoic acid
Number of subjects: 0
Study 1023955 — intervention group
Group type: COMPARATOR
Intervention: Diazepam in cremophor EL
Number of subjects: 0
Study 31992266 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid off-job crafting intervention including on-site training, individual off-job crafting plan, smartphone app usage, and reflection training.
Number of subjects: 0
Study 31992266 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 31662165 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led group
Number of subjects: 109
Study 31662165 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-led group
Number of subjects: 109
Study 28981592 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SVV group
Number of subjects: 80
Study 26014292 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane (10:1 ratio with doxorubicin, cumulative dose of 100 to 360 mg/m2)
Number of subjects: 1008
Study 26014292 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin without dexrazoxane
Number of subjects: 1008
Study 26014292 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 1008
Study 23862400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sodium hyaluronate 9 mg twice daily for 30 days
Number of subjects: 36
Study 23862400 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 36
Study 23862400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sodium hyaluronate
Number of subjects: 36
Study 21415611 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized telecare management augmented by automated symptom monitoring (ASM)
Number of subjects: 202
Study 18579227 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol)
Number of subjects: 400
Study 18579227 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin plus clopidogrel)
Number of subjects: 400
Study 17875857 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cancer in the head and neck region
Number of subjects: 10
Study 17875857 — intervention group
Group type: COMPARATOR
Intervention: Community control subjects
Number of subjects: 10
Study 15479288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water
Number of subjects: 3983
Study 15479288 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 3983
Study 10716083 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (1 x 400 mg tablet in the morning and 1 placebo tablet in the evening for 7 days)
Number of subjects: 12
Study 10716083 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (1 x 500 mg tablet in the morning and 1 x 500 mg tablet in the evening for 7 days)
Number of subjects: 12
Study 8799769 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisaccades with unpredictable target location
Number of subjects: 0
Study 8799769 — intervention group
Group type: COMPARATOR
Intervention: Pro-target saccades with unpredictable target location
Number of subjects: 0
Study 8799769 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisaccades with both target position and type of saccade unpredictable
Number of subjects: 0
Study 8799769 — intervention group
Group type: COMPARATOR
Intervention: Pro-target saccades with both target position and type of saccade unpredictable
Number of subjects: 0
Study 8799769 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisaccades with predictable target location and unpredictable type of saccade
Number of subjects: 0
Study 8799769 — intervention group
Group type: COMPARATOR
Intervention: Pro-target saccades with predictable target location and unpredictable type of saccade
Number of subjects: 0
Study 8799769 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisaccades with both target position and type of saccade predictable
Number of subjects: 0
Study 8799769 — intervention group
Group type: COMPARATOR
Intervention: Pro-target saccades with both target position and type of saccade predictable
Number of subjects: 0
Study 1452797 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium chloride hexahydrate dentifrices with diatomaceous earth
Number of subjects: 0
Study 1452797 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium chloride hexahydrate dentifrices with silica-based abrasive system
Number of subjects: 0
Study 1452797 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 4092799 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) taken with breakfast; four types of breakfast differing by lipid content.
Number of subjects: 103
Study 31301609 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily patient-reported anxiety measured using smartphones
Number of subjects: 84
Study 28840585 — intervention group
Group type: EXPERIMENTAL
Intervention: Quxie Capsule combined with conventional therapy
Number of subjects: 60
Study 28840585 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with conventional therapy
Number of subjects: 60
Study 26979583 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-2 (2 Large High-Protein meals)
Number of subjects: 10
Study 26979583 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-6 (6 Small High-Protein meals)
Number of subjects: 10
Study 26979583 — intervention group
Group type: COMPARATOR
Intervention: CON-2 (2 Large Low-Protein meals)
Number of subjects: 10
Study 25556888 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training program (eccentric hamstring muscle strength, plyometrics, and free/resisted sprinting exercises)
Number of subjects: 60
Study 25556888 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training program
Number of subjects: 60
Study 25556888 — intervention group
Group type: COMPARATOR
Intervention: Regular football training (Control Group)
Number of subjects: 60
Study 23546864 — intervention group
Group type: EXPERIMENTAL
Intervention: Double crown of spiral tackers (DC)
Number of subjects: 76
Study 23546864 — intervention group
Group type: COMPARATOR
Intervention: Sutures and tackers (S&T)
Number of subjects: 76
Study 19959609 — intervention group
Group type: EXPERIMENTAL
Intervention: Goshgarian palatal arch
Number of subjects: 57
Study 19959609 — intervention group
Group type: COMPARATOR
Intervention: Nance palatal arch
Number of subjects: 57
Study 19959609 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Goshgarian and Nance palatal arches
Number of subjects: 57
Study 18798438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervex-brush
Number of subjects: 1658
Study 18798438 — intervention group
Group type: COMPARATOR
Intervention: Cervex-mex
Number of subjects: 1658
Study 16829344 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat diet (PUFA)
Number of subjects: 70
Study 16829344 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fat diet (SAFA)
Number of subjects: 70
Study 16829344 — intervention group
Group type: COMPARATOR
Intervention: High PUFA diet
Number of subjects: 70
Study 16829344 — intervention group
Group type: COMPARATOR
Intervention: High SAFA diet
Number of subjects: 70
Study 14638346 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 14638346 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and Meperidine
Number of subjects: 20
Study 10971543 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital X-ray radiogrammetry (DXR) method
Number of subjects: 40
Study 8844447 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY x 1005 (250 mg twice daily)
Number of subjects: 12
Study 8844447 — intervention group
Group type: EXPERIMENTAL
Intervention: theophylline (400 mg twice daily)
Number of subjects: 12
Study 8844447 — intervention group
Group type: COMPARATOR
Intervention: BAY x 1005 and theophylline concomitantly (treatment C)
Number of subjects: 12
Study 1621751 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef (200 mg, twice daily)
Number of subjects: 393
Study 1621751 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (250 mg, three times daily)
Number of subjects: 393
Study 1621751 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 393
Study 1621751 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 393
Study 6463091 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (5-30 mg)
Number of subjects: 0
Study 6463091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30368666 — intervention group
Group type: EXPERIMENTAL
Intervention: EBC–DNA analysis for KRAS mutation
Number of subjects: 51
Study 30368666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer tissue analysis for KRAS mutation
Number of subjects: 51
Study 30368666 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of KRAS mutations at codon 12
Number of subjects: 51
Study 30368666 — intervention group
Group type: COMPARATOR
Intervention: Normal lung tissue analysis
Number of subjects: 51
Study 28741741 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 34
Study 28741741 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin after low dose of morphine
Number of subjects: 34
Study 26803590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 treatment
Number of subjects: 2381
Study 26803590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 and folic acid/B12 treatment
Number of subjects: 2381
Study 26803590 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2381
Study 26803590 — intervention group
Group type: COMPARATOR
Intervention: Folic acid/B12 treatment
Number of subjects: 2381
Study 23369770 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-actuated nebulizer (BAN)
Number of subjects: 54
Study 23369770 — intervention group
Group type: COMPARATOR
Intervention: Handheld nebulizer (HHN)
Number of subjects: 54
Study 23377603 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face self-management educational program
Number of subjects: 61
Study 23377603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study 20035492 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss group (5% body weight reduction)
Number of subjects: 14
Study 20035492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no weight reduction)
Number of subjects: 14
Study 20035492 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss group
Number of subjects: 14
Study 18753861 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 1 mg once daily for 24 weeks
Number of subjects: 68
Study 18753861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 18753861 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir for 48 weeks
Number of subjects: 68
Study 18753861 — intervention group
Group type: COMPARATOR
Intervention: Entecavir and Placebo (both groups)
Number of subjects: 68
Study 15923264 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 32
Study 12540412 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (500 mg at -90 and 0 min)
Number of subjects: 7
Study 12540412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 10553750 — intervention group
Group type: EXPERIMENTAL
Intervention: Community reintegration skills training
Number of subjects: 32
Study 10553750 — intervention group
Group type: COMPARATOR
Intervention: Supportive group therapy
Number of subjects: 32
Study 8510517 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant growth hormone (rGH) therapy for 12 months
Number of subjects: 16
Study 8510517 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated children)
Number of subjects: 16
Study 2881420 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (100 micrograms/kg)
Number of subjects: 5
Study 2881420 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 micrograms/kg)
Number of subjects: 5
Study 2881420 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (3 micrograms/kg)
Number of subjects: 5
Study 2881420 — intervention group
Group type: COMPARATOR
Intervention: Guanfacine (15 micrograms/kg)
Number of subjects: 5
Study 31342226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum CCFM8610
Number of subjects: 109
Study 31342226 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum CCFM16
Number of subjects: 109
Study 31342226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 31342226 — intervention group
Group type: COMPARATOR
Intervention: Oligosaccharides
Number of subjects: 109
Study 28801034 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimulation plus standard pelvic floor muscle training
Number of subjects: 114
Study 28801034 — intervention group
Group type: COMPARATOR
Intervention: Standard pelvic floor muscle training alone
Number of subjects: 114
Study 28801034 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimulation plus standard pelvic floor muscle training and Standard pelvic floor muscle training alone
Number of subjects: 114
Study 27223641 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg orally, twice daily preoperatively, and 0.5 mg, twice daily until hospital discharge)
Number of subjects: 140
Study 27223641 — intervention group
Group type: COMPARATOR
Intervention: Control group (no colchicine)
Number of subjects: 140
Study 25862614 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-meal frequency (2 MF)
Number of subjects: 11
Study 25862614 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-meal frequency (6 MF)
Number of subjects: 11
Study 25862614 — intervention group
Group type: COMPARATOR
Intervention: Both 2 MF and 6 MF
Number of subjects: 11
Study 24519692 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 2.5 mg
Number of subjects: 25
Study 24519692 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg
Number of subjects: 25
Study 24519692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 21788602 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous lowering of systolic blood pressure and LDL cholesterol
Number of subjects: 413
Study 21788602 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved systolic blood pressure
Number of subjects: 413
Study 21788602 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved LDL cholesterol
Number of subjects: 413
Study 21788602 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower achieved levels of systolic blood pressure
Number of subjects: 413
Study 19464465 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 94
Study 19464465 — intervention group
Group type: COMPARATOR
Intervention: Atrioventricular universal pacing
Number of subjects: 94
Study 19464465 — intervention group
Group type: COMPARATOR
Intervention: Atrial inhibited pacing
Number of subjects: 94
Study 16455420 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic Doppler echocardiography (TTDE) measuring coronary flow velocity reserve (CFVR)
Number of subjects: 107
Study 16455420 — intervention group
Group type: COMPARATOR
Intervention: Tl‐201 single‐photon emission computed tomography (SPECT)
Number of subjects: 107
Study 15767982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle peak systolic velocity (APSV)
Number of subjects: 63
Study 11737108 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay graft associated with a non-resorbable membrane
Number of subjects: 0
Study 11737108 — intervention group
Group type: COMPARATOR
Intervention: Onlay graft alone
Number of subjects: 0
Study 10461448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten 400 mg or 9 mg/kgbw/day (Group B)
Number of subjects: 131
Study 10461448 — intervention group
Group type: COMPARATOR
Intervention: Parenteral therapy (Group A)
Number of subjects: 131
Study 10461448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (Group B)
Number of subjects: 131
Study 8150836 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase ointment and polymyxin B sulfate/bacitracin spray
Number of subjects: 15
Study 8150836 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine cream
Number of subjects: 15
Study 2681858 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 13
Study 4343464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sedation with diazepam alone
Number of subjects: 65